The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score.
In acute myeloid leukemia (AML) patients, a variety of clinical and biologic parameters, including phenotype, have been examined for potential value in predicting treatment response and survival. The European Group for the Immunological Classification of Leukaemias (EGIL) has proposed that AML be defined immunologically by the expression of 2 or more of the following myeloid markers: myeloperoxidase, CD13, CD33, CDw65, and CD117. With regard to this classification, the prognostic significance of 21 antigens taken separately and with immunophenotypic subgroups were evaluated and compared with other clinical and biological variables in 177 adult AML patients. None of the antigens tested were associated with treatment outcome. In contrast, patients with blasts disclosing a full expression of panmyeloid phenotype (defined by the expression of all 5 myeloid markers) had a higher complete remission rate (P <. 0001) and differed significantly in disease-free survival (P =.02) and overall survival (P =.008) than patients whose cells expressed fewer than 5 of these markers. In multivariate analysis, only age, panmyeloid phenotype, performance status, and permeability glycoprotein activity influence treatment outcome. Cytogenetics was significant in univariate analysis but not in multivariate analysis, most likely because of the redundancy with panmyeloid phenotype and a higher sensitivity of immunophenotyping. Patients whose cells exhibit the panmyeloid phenotype appear to define a relatively homogeneous biological subset of AML. The 4 independent prognostic factors were used to create a prognostic score, defined by the number of factors present. This score permitted a stratification of patients with AML, thereby allowing for the consideration of innovative therapies to improve outcome in the poorer outcome groups.
Formation de Recherche Claude Bernard, Institute National de la Santé et de la Recherche Médicale (INSERM), Université Paris, and the Services d'Hématologie Biologique et Clinique, Hôpital Hôtel-Dieu, Paris, France.
O
O
Legrand
J Y
JY
Perrot
M
M
Baudard
A
A
Cordier
R
R
Lautier
G
G
Simonin
R
R
Zittoun
N
N
Casadevall
J P
JP
Marie
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D015415:Biomarkers; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome
D015703:Antigens, CD; D015415:Biomarkers